Skip to content
Angion Biomedica Corp

Angion Biomedica Corp

ANGION IS A LATE-STAGE CLINICAL COMPANY DEVELOPING SMALL MOLECULES TARGETING ACUTE ORGAN INJURY AND CHRONIC FIBROSIS

  • about
    • executive management
    • scientific advisory board
    • board of directors
  • our science
    • organ fibrosis
    • HGF/c-met pathway
  • pipeline
    • ANG-3070
    • ANG-3777
    • ROCK2 Inhibitor
    • CYP11B2 Inhibitor
  • Investors
    • stock information
      • stock quote & chart
      • historic price lookup
    • analyst coverage
    • press releases
    • events & presentations
    • sec filings
    • governance
    • investor resources
      • investor contact
      • investor FAQs
      • email alerts
  • publications
  • careers
  • contact

RSL-AKI

Hospital-acquired acute kidney injury and hospital readmission: A cohort study (Koulouridis, et al)


February 2015 – American Journal of Kidney Diseaes
Posted in RSL-AKI

Acute kidney injury (Bellomo, et al)


August 2012 – Lancet
Posted in RSL-AKI

Acute kidney injury: What’s the prognosis? (Murugan & Kellum)


April 2011 – Nature Reviews Nephrology
Posted in RSL-AKI

Duration of acute kidney injury impacts long-term survival after cardiac surgery (Brown, et al)


October 2010 – The Annals Thoracic Surgery
Posted in RSL-AKI

Acute kidney injury predicts outcomes of non-critically ill patients (Barrantes, et al)


May 2009 – Mayo Clinic Proceedings
Posted in RSL-AKI

Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery (Hobson, et al)


May 2009 – Circulation
Posted in RSL-AKI

Preoperative risk factors for the development of acute renal failure in cardiac surgery (Kochi, et al)


March 2007 – Brazilian Journal of Cardiovascular Surgery
Posted in RSL-AKI

Incidence and outcomes in acute kidney injury: A comprehensive population-based study (Ali, et al)


April 2007 – Journal of the American Society of Nephrology
Posted in RSL-AKI

Comparison of early renal function parameters for the prediction of 5-year graft survival after kidney transplantation (Schnuelle, et al)


January 2007 – Nephrology Dialysis Transplantation
Posted in RSL-AKI

Posts navigation

Newer posts

CATEGORIES

  • RSL-HGF
  • RSL-ALI
  • Fibrosis
  • ROCKi
  • angion publications
  • RSL-AKI
  • events

CORPORATE ADDRESS

7 Wells Avenue
Suite 14
Newton, MA 02459

Navigation

  • home
  • about
  • our science
  • pipeline
  • investors
  • publications
  • careers
  • contact

© 2023 Angion. All Rights Reserved.
Legal and Privacy Policy

BOSTON | AUSTRALIA